



JG18 PCT/PTO 22 APR 2002

Bot-seq
#6

DOCKET: 46342/56,721

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: H. Kikutani, et al.
Serial No: 10/009,330
Filed: December 3, 2001
For: SCREENING METHOD USING CD100

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on April 12, 2002.

By: _____

Donna M. Tomaso

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

Applicants submit the following documents as follows:

1. Submission of "Sequence Listing", Computer Readable Copy, and/or Amendment Pertaining Thereto for Biotechnology Invention Containing Nucleotide and/or Amino Acid Sequence (Transmittal);
2. Copy of Notice to Comply dated February 12, 2002.
3. 3.5" Floppy Disk Containing the Sequence Listing,


H. Kikutani, et al.
USSN: 10/009,330
Page 2

4. Statement in Support of Filing and Submission in accordance with 37 CFR
§§1.821-1.825 and Sequence Listing Computer Printout;

Respectfully submitted,

Date: April 12, 2002

By: _____


John B. Alexander, Ph.D.
Reg. No. 48,399
Attorney for Applicant(s)

Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
Customer No. 21874
(617) 439-4444
297855



Practitioner's Docket No. 46342/56,721
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: H. Kikutani, et al.
Application No.: 10/009,330
Filed: December 3, 2001
For: SCREENING METHOD USING CD100

Group No.: Unassigned
Examiner: Unassigned

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

**SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,
AND/OR AMENDMENT PERTAINING THERETO
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE**

(check and complete this item, if applicable)

1. ☒ This replies to the Office Letter DATED February 12, 2002

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the application number from the return post card or the attorney's docket number added.

☒ A copy of the Office Letter is enclosed.

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, John B. Alexander, Ph.D
(type or print name of person signing below)

state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith is/are:

(check each item as applicable)

- A. ☒ "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application.
Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.

- B. ☐ An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C. ☒ A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D. ☐ Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:
Application No.: 0 /
Filed:
For:

Group No.:
Examiner:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form
(other application)

"Sequence Identifier"
(this application)

NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference maybe made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. Section 1.821(e).

- E. ☒ A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. Section 1.821(g).
- ☐ Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. Section 1.821(b).
- F. ☒ Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.
- ☐ Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

**STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

(complete applicable item A and/or B)

- A. ☒ Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. ☒ All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

STATUS

5. Applicant is

☐ a small entity. A statement:

☐ is attached.

☐ was already filed.

☒ other than a small entity.

EXTENSION OF TERM

6.

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).

NOTE: See 37 C.F.R. Section 1.645 for extensions of time in interference proceedings and 37 C.F.R. Section 1.550(c) for extensions of time in reexamination proceedings.

7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.

(complete (a) or (b) as applicable)

- (a) ☒ Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:

Extension (months)	Fee for other than small entity	Fee for small entity
<input type="checkbox"/> one month	\$ 110.00	\$ 55.00
<input type="checkbox"/> two months	\$ 400.00	\$ 200.00
<input type="checkbox"/> three months	\$ 920.00	\$ 460.00
<input type="checkbox"/> four months	\$1440.00	\$ 720.00

Fee \$ _____

If an additional extension of time is required, please consider this a petition therefor.
(check and complete the next item, if applicable)

- ☐ An extension for _____ months has already been secured, and the fee paid therefor of \$ _____ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$ _____

OR

- (b) ☒ Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

FEE PAYMENT

8. ☐ Attached is a check in the sum of \$ _____.

- ☐ Charge Account No. _____ the sum of \$ _____.
A duplicate of this transmittal is attached.

FEE DEFICIENCY

9.

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.

10. [X] If any additional extension and/or fee is required, charge Account No. 04-1105

SIGNATURE(s)

John B. Alexander, Ph.D.

(type or print name of person signing statement)

Signature

April 12, 2002

Date

**Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
P. O. Box 9169,
Boston, MA 02209**

(If applicable)

Tel. No.: (617) - 439-4444

Fax Nos.: (617) 439-4170

Customer No.: 21874

☐ Inventor

☐ Assignee of complete interest

☐ Person authorized to sign on behalf of assignee

☒ Practitioner of record

☐ Filed under Rule 34(a)

☒ **Registration No. 48,399**

☐ Other

(specify identity of person signing)

(complete the following, if applicable)

(type name of assignee)

Address of assignee

Title of person authorized to sign on behalf of assignee

A "STATEMENT UNDER 37 C.F.R. Section 3.73(b)" is attached.

Assignment recorded in PTO on _____
Reel _____ Frame _____

SIGNATURE OF PRACTITIONER

Reg. No.

(type or print name of practitioner)

Tel. No.: ()


P.O. Address

Customer No.:

298345



UNITED STATES PATENT AND TRADEMARK OFFICE




Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/009,330	Hitoshi kikutani	46342/56,721

INTERNATIONAL APPLICATION NO.
PCT/JP00/03558

I.A. FILING DATE	PRIORITY DATE
06/01/2000	06/03/1999

Cara Z Lowen
 Dike Bronstein Roberts & Cushman
 P O Box 9169
 Boston, MA 02209



CONFIRMATION NO. 3836

371 FORMALITIES LETTER



OC000000007452830

Date Mailed: 02/12/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Assignee Statement
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration

Sequence Listing
 Edwards & Angell LLP
 Dike, Bronstein, Roberts & Cushman
 101 Federal St. Boston, MA 02110
 Date Rec'd 2/21/02
 Docketed For Apr. 12 - Aug. 12, 2002
 By KRD
 Approved [Signature] 2/21/02

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the

requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- RAW SEQUENCE LISTING ERROR REPORT
- APPLICANT MUST PROVIDE:
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

• For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

FREDERICK SMITH


Telephone: (703) 305-3654

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/009,330	PCT/JP00/03558	46342/56,721

FORM PCT/DO/EO/905 (371 Formalities Notice)

BIOTECHNOLOGY
SYSTEMS
BRANCH



**RAW SEQUENCE LISTING
ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/009,330
Source: PCR/10
Date Processed by STIC: 1/14/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER
VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom, including:

1. EFS-Bio (<<http://www.uspto.gov/ebs/efs/downloads/documents.htm>> , EFS Submission

User Manual - ePAVE)

2. U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202

3. Hand Carry directly to:

U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202

Or

U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
2011 South Clark Place, Arlington, VA 22202

4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Raw Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER:

14009330

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SO

- 1 Wrapped Nucleics
 Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2 Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 Misaligned Amino
 Numbering The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4 Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 Variable Length Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 PatentIn 2.0
 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7 Skipped Sequences
 (OLD RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
 (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
 (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading).
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
 This sequence is intentionally skipped

 Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8 Skipped Sequences
 (NEW RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence.
 <210> sequence id number
 <400> sequence id number
 000
- 9 Use of n's or Xaa's
 (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
 Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
 In <220> to <223> section, please explain location of n or Xaa; and which residue n or Xaa represents.
- 10 Invalid <213>
 Response Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11 Use of <220> Sequence(s) 10 missing the <220> "Feature" and associated numeric identifiers and responses.
 Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
 (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 PatentIn 2.0
 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 Misuse of n n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

PCT10

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/009,330

DATE: 01/14/2002

TIME: 13:43:57

Input Set : A:\Sequence Listing.txt

Output Set: N:\CRF3\01142002\J009330.raw

Does Not Comply
Corrected Diskette Needed

3 <110> APPLICANT: Takeda Chemical Industries, Ltd.
W--> 4 <120> TITLE OF INVENTION: Screening Method Using CD100
W--> 5 <130> FILE REFERENCE: 2611WOOP
C--> 6 <140> CURRENT APPLICATION NUMBER: US/10/009,330
C--> 6 <141> CURRENT FILING DATE: 2001-12-03
6 <150> PRIOR APPLICATION NUMBER: JP 11-157111
7 <151> PRIOR FILING DATE: 1999-06-03
W--> 8 <160> NUMBER OF SEQ ID: 10

ERRORED SEQUENCES

413 <210> SEQ ID NO: 6 1337 shown

414 <211> LENGTH: 1357

415 <212> TYPE: DNA

416 <213> ORGANISM: Mouse

W--> 417 <400> SEQUENCE: 6

418 tgggaagactg tgaagcagag gcgcccaggg ctatggctga cgctatcacg tatgcagacc 60
419 tgcgctttgt gaaagtgtccc ctgaagaaca gcgcatctaa ccatctagga caggactgtg 120
420 aggcctatga agatggggaa ctcacctacg agaattgtgca agtgtctcca gtcccaggag 180
421 ggccaccagg cttggcttcc cctgcactag cggacaaagc aggggtcggg tcagagcaac 240
422 caactgcgac ctggagctct gtgaactcgt ctgctctcag gcagattccc cgctgtccta 300
423 cagtctgctt gcaatacttc ttgcttggcc ttctcgtgtc ctgctctgat ttaggggtgg 360
424 ctgtcatctg cctgggagtt cgctatctgc aggtgtctcg gcagttccag gaggggacca 420
425 ggatttgga agccaacaat agcagcctgc agcagcagct cagggagaag ataagtcagc 480
426 tggggcagaa ggaggtggag ctccagaagg ctcggaaga gctgatctcg agccaggaca 540
427 cattacagga gaagcagagg actcacgagg acgctgagca gcaactacaa gcctgccagg 600
428 ctgagagagc gaagaccaag gagaacctga aaactgagga ggagcggagg agggacctgg 660
429 accagaggtt gacaagcacg cgggagacac tgaggcgctt cttctctgat tcatcagaca 720
430 cctgctgtcc atgcggatgg attccatattc aggaagggtg cttttacatc tcacataccc 780
431 tcggaagtct ggaggagagc caaaaatact gcacatctct gtccctccaaa ctggcagcat 840
432 tcgatgaacc ttctaagtat tactatgaag tttctctgcc cagcggctta gaggagttgc 900
433 tagatcgctt gaagtcatat tggatacaga tgagcaagaa gtggaggcag gactctgact 960
434 ctcaaagccg acattgtgtc aggataaaaa catattacca gaagtggaa agaacaattt 1020
435 ccaagtgtgc agagcttcac ccctgcattt gtgagtcgga ggctttcagg tttcctgatg 1080
436 ggatcaatct gaactgaaac ggacacttga acaagacctt gtgacctaca tccttaacct 1140
437 acggcctgcc aatttttaag actgctattc ctccagcact ccctcactct cgggcatgcc 1200
438 cagctaaggg atgacctgct gcttgcttga aagctgctcc agaaactgga cttctcttgg 1260
E--> 439 gaagagtaaa gaagcctcca gaaaagactt gaccttcctt aagaacttcc caaactagag 1340 1320
E--> 440 atgggtcagg ggagggc 1357 1337

531 <210> SEQ ID NO: 10

532 <211> LENGTH: 53

533 <212> TYPE: DNA

534 <213> ORGANISM: Artificial Sequence

W--> 535 <220> FEATURE:

536 <223> OTHER INFORMATION:

W--> 537 <400> SEQUENCE: 10

see item 11 on Err Summary Sheet
see next page

RAW SEQUENCE LISTING

DATE: 01/14/2002

PATENT APPLICATION: US/10/009,330

TIME: 13:43:57

Input Set : A:\Sequence Listing.txt

Output Set: N:\CRF3\01142002\J009330.raw

538 gacggatcct acttactttg ctttgcttgc ttgagataca ccgtcttctc tga 53
E--> 543 (1) *delete*

VERIFICATION SUMMARY

DATE: 01/14/2002

PATENT APPLICATION: US/10/009,330

TIME: 13:43:58

Input Set : A:\Sequence Listing.txt

Output Set: N:\CRF3\01142002\J009330.raw

L:4 M:283 W: Missing Blank Line separator, <120> field identifier
L:5 M:283 W: Missing Blank Line separator, <130> field identifier
L:6 M:270 C: Current Application Number differs, Replaced Current Application No
L:6 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:8 M:283 W: Missing Blank Line separator, <160> field identifier
L:9 M:283 W: Missing Blank Line separator, <210> field identifier
L:13 M:283 W: Missing Blank Line separator, <400> field identifier
L:126 M:283 W: Missing Blank Line separator, <400> field identifier
L:178 M:283 W: Missing Blank Line separator, <400> field identifier
L:291 M:283 W: Missing Blank Line separator, <400> field identifier
L:366 M:283 W: Missing Blank Line separator, <400> field identifier
L:417 M:283 W: Missing Blank Line separator, <400> field identifier
L:439 M:254 E: No. of Bases conflict, LENGTH:Input:1340 Counted:1320 SEQ:6
M:254 Repeated in SeqNo=6
L:440 M:252 E: No. of Seq. differs, <211>LENGTH:Input:1357 Found:1337 SEQ:6
L:445 M:283 W: Missing Blank Line separator, <400> field identifier
L:496 M:283 W: Missing Blank Line separator, <400> field identifier
L:527 M:283 W: Missing Blank Line separator, <220> field identifier
L:529 M:283 W: Missing Blank Line separator, <400> field identifier
L:535 M:283 W: Missing Blank Line separator, <220> field identifier
L:537 M:283 W: Missing Blank Line separator, <400> field identifier
L:543 M:254 E: No. of Bases conflict, LENGTH:Input:1 Counted:53 SEQ:10